significant results were also observed at both time points for reduced symptom severity (ibs-sss, p = .008 and p = .03) and adequate relief (ibs-ar, p = .02 and p = .03); and a trend favoring open-label placebo was observed for quality of life (ibs-qol) at the 21-day endpoint (p = .08).